270 related articles for article (PubMed ID: 10378706)
1. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.
Denton CP; Bunce TD; Dorado MB; Roberts Z; Wilson H; Howell K; Bruckdorfer KR; Black CM
Rheumatology (Oxford); 1999 Apr; 38(4):309-15. PubMed ID: 10378706
[TBL] [Abstract][Full Text] [Related]
2. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis.
Bruckdorfer KR; Hillary JB; Bunce T; Vancheeswaran R; Black CM
Arthritis Rheum; 1995 Aug; 38(8):1060-7. PubMed ID: 7639801
[TBL] [Abstract][Full Text] [Related]
3. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
[TBL] [Abstract][Full Text] [Related]
4. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
5. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
Lee HS; Jeong JY; Kim BC; Kim YS; Zhang YZ; Chung HK
Kidney Int; 1997 Apr; 51(4):1151-9. PubMed ID: 9083281
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia.
Dujovne CA; Harris WS; Gerrond LL; Fan J; Muzio F
Am J Cardiol; 1994 Jul; 74(1):38-42. PubMed ID: 8017303
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
9. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
[TBL] [Abstract][Full Text] [Related]
10. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.
Simonini G; Pignone A; Generini S; Falcini F; Cerinic MM
Toxicology; 2000 Nov; 155(1-3):1-15. PubMed ID: 11154792
[TBL] [Abstract][Full Text] [Related]
11. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
12. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
[TBL] [Abstract][Full Text] [Related]
14. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.
Herrick AL; Rieley F; Schofield D; Hollis S; Braganza JM; Jayson MI
J Rheumatol; 1994 Aug; 21(8):1477-83. PubMed ID: 7983650
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Coleiro B; Marshall SE; Denton CP; Howell K; Blann A; Welsh KI; Black CM
Rheumatology (Oxford); 2001 Sep; 40(9):1038-43. PubMed ID: 11561116
[TBL] [Abstract][Full Text] [Related]
17. Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients.
Lussier-Cacan S; Dubreuil-Quidoz S; Roederer G; Leboeuf N; Boulet L; de Langavant GC; Davignon J; Naruszewicz M
Arterioscler Thromb; 1993 Dec; 13(12):1790-7. PubMed ID: 8241099
[TBL] [Abstract][Full Text] [Related]
18. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
19. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
20. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
Kahan A; Amor B; Menkes CJ
Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
